Please assess the completion status of the following clinical trial:

Trial Title: Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of ductal carcinoma in situ (DCIS) on core biopsy~* No evidence of contralateral breast disease or palpable masses on breast examination~* No presence or suspicion of invasive cancer, including contralateral invasive cancer, on core biopsy and MRI~* No documented ipsilateral axillary adenopathy~* Planning to undergo lumpectomy or mastectomy~* Estrogen receptor (ER)-positive tumor by immunohistochemistry~PATIENT CHARACTERISTICS:~* Female patient~* Premenopausal or postmenopausal~  * Postmenopausal is defined by any of the following:~    * No spontaneous menses for \>= 1 year~   * Bilateral oophorectomy~   * Radiation castration and amenorrheic for \>= 3 months~   * Follicle-stimulating hormone (FSH) \> 20 IU/L AND off all hormonal therapy (e.g., hormone replacement therapy or birth control pills) for \>= 1 month~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No co-morbidities contraindicating the use of tamoxifen, including any of the following:~  * Prior history of thrombotic events~ * History of hypercoagulable state~ * History of endometrial hyperplasia~ * Abnormal vaginal bleeding~* No history of contrast dye-related allergies/reactions~* No history of metal-containing prostheses or implants~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tamoxifen or letrozole (Type: EXPERIMENTAL): tamoxifen or letrozole work in treating women with ductal carcinoma in situ

Based on this trial design, predict the completion outcome and termination type (if applicable).